Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Free Report) Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $9.17, for a total transaction of $104,968.99. Following the transaction, the director now directly owns 7,186,913 shares of the company’s stock, valued at approximately $65,903,992.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Blake Borgeson also recently made the following trade(s):

  • On Tuesday, April 30th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.95, for a total value of $91,003.65.
  • On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.66, for a total value of $87,684.02.
  • On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total transaction of $100,962.54.
  • On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.79, for a total transaction of $216,382.66.
  • On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.06, for a total transaction of $241,851.24.

Recursion Pharmaceuticals Stock Down 6.7 %

RXRX opened at $8.28 on Friday. The firm’s fifty day simple moving average is $8.82 and its two-hundred day simple moving average is $9.66. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.97 and a 52-week high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The firm had revenue of $13.80 million for the quarter, compared to analyst estimates of $11.10 million. During the same period last year, the company posted ($0.34) EPS. Recursion Pharmaceuticals’s quarterly revenue was up 14.0% compared to the same quarter last year. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.6 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. KeyCorp raised their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th. Needham & Company LLC restated a “buy” rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a research report on Friday, May 10th.

Check Out Our Latest Research Report on Recursion Pharmaceuticals

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Recursion Pharmaceuticals during the first quarter worth approximately $26,000. National Bank of Canada FI grew its holdings in shares of Recursion Pharmaceuticals by 90.9% during the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after buying an additional 1,500 shares in the last quarter. First Horizon Advisors Inc. purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $47,000. Allspring Global Investments Holdings LLC raised its position in shares of Recursion Pharmaceuticals by 25.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock valued at $77,000 after buying an additional 2,050 shares during the last quarter. Finally, Private Advisor Group LLC purchased a new position in shares of Recursion Pharmaceuticals in the third quarter worth about $79,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Featured Stories

Insider Buying and Selling by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.